MT-6402-001 MT-6402-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

NCT04795713

MT-6402-001: A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

Associated Conditions

Multiple Tumor Types

Principal Investigator

Guru Sonpavde

Sponsor

Molecular Templates, Inc. (mTem)

To evaluate the safety and tolerability of MT-6402 in subjects
with advanced cancer (solid tumors)
and to estimate the maximum tolerated
dose (MTD). To evaluate efficacy of
MT-6402 in subjects with advanced
cancer by using objective response rate (ORR).